Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23038IDB-L5

Select Item

Empower your strategies with our Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024 report and make more profitable business decisions.

Recurrent glioblastoma multiforme (GBM) refers to the return of aggressive brain tumors known as glioblastomas after initial treatment. GBM is the most malignant type of glioma, characterized by rapid growth and infiltrative behavior. Despite aggressive therapies like surgery, radiation, and chemotherapy, GBM often recurs due to its invasive nature and resistance to treatment. Management of recurrent GBM poses significant challenges. Treatment options may include additional surgery, re-irradiation, or alternative chemotherapy regimens. Clinical trials exploring novel therapies, immunotherapy, and targeted approaches aim to improve outcomes for patients facing recurrent GBM. However, the prognosis remains generally poor, emphasizing the critical need for ongoing research and innovative treatments in the field of neuro-oncology.

The Recurrent Glioblastoma Multiforme (GBM) drugs in development market research report provide comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Recurrent Glioblastoma Multiforme (GBM) and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Recurrent Glioblastoma Multiforme (GBM)
Key Targets
· Epidermal Growth Factor Receptor ERB1; Vascular Endothelial Growth Factor Receptor 2; Programmed Cell Death Protein 1; DNA; Vascular Endothelial Growth Factor A; Receptor Tyrosine Protein Kinase ERBB 2; Interleukin 13 Receptor Subunit Alpha 2; Cyclin Dependent Kinase 4; Cyclin Dependent Kinase 6; and Vascular Endothelial Growth Factor Receptor
Key Mechanisms of Action
· Vascular Endothelial Growth Factor A Inhibitor; Programmed Cell Death Protein 1 Antagonist; Epidermal Growth Factor Receptor ERB1 Inhibitor; Vascular Endothelial Growth Factor Receptor 2 Inhibitor; Vascular Endothelial Growth Factor Receptor Inhibitor; DNA Inhibitor; Cyclin Dependent Kinase 4 Inhibitor; Cyclin Dependent Kinase 6 Inhibitor; Platelet Derived Growth Factor Receptor Beta Inhibitor; and Poly [ADP Ribose] Polymerase 1 Inhibitor
Key Routes of Administration
· Intravenous; Oral; Intratumor; Parenteral; Subcutaneous; Intradermal; Intracerebral; Intraperitoneal; Intramuscular; and Intrathecal
Key Molecule Types
· Small Molecule; Gene-Modified Cell Therapy; Monoclonal Antibody; Cell Therapy; Oncolytic Virus; Subunit Vaccine; Peptide; Fusion Protein; Gene Therapy; and Synthetic Peptide
Major Companies
· Bristol-Myers Squibb Co; Advanced Accelerator Applications SA; AstraZeneca Plc; Incyte Corp; ImmunityBio Inc; Merck & Co Inc; Mustang Bio Inc; Merck KGaA; F. Hoffmann-La Roche Ltd; and Bayer AG

Scope

  • Therapeutics in Development: Covering 164 molecules, with 142 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Recurrent Glioblastoma Multiforme (GBM) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Recurrent Glioblastoma Multiforme (GBM) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Recurrent Glioblastoma Multiforme (GBM) treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

Accendatech Co Ltd
Adlai Nortye Biopharma Co Ltd
Advanced Accelerator Applications SA
Alaunos Therapeutics Inc
AngioChem Inc
Apogenix AG
Arcus Biosciences Inc
Ariceum Therapeutics GmbH
Arog Pharmaceuticals Inc
Ascletis Pharma Inc
AstraZeneca Plc
Aucentra Therapeutics Pty Ltd
Aveta Biomics Inc
Basilea Pharmaceutica Ltd
Bayer AG
BeiGene Ltd
Beijing DCTY Biotech Co Ltd
Beijing Pearl Biotechnology LLC
Beijing Sanbo Brain Hospital
Beijing Tiantan Affiliated Hospital
BerGenBio ASA
Bexion Pharmaceuticals Inc
BeyondBio Inc
Bio-Thera Solutions Ltd
Biocon Ltd
Biodexa Pharmaceuticals PLC
Biohaven Ltd
Black Diamond Therapeutics Inc
Boehringer Ingelheim International GmbH
BoYuan RunSheng Pharma Hangzhou Co Ltd
Bristol-Myers Squibb Co
Candel Therapeutics Inc
CHA Biotech Co Ltd
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimeric Therapeutics Ltd
Chimerix Inc
CNS Pharmaceuticals Inc
Crimson BioPharm Inc
Cytea Bio
Cyteph Pty Ltd
Daiichi Sankyo Co Ltd
DNAtrix Inc
Duke University
Duke University Medical Center
Eisai Co Ltd
Elevar Therapeutics Inc
Eli Lilly and Co
Endeavour College of Natural Health
Enterome Bioscience SA
Epygen Biotech Pvt Ltd
Erasca Inc
ERC Belgium SA
Eydis Bio Inc
F. Hoffmann-La Roche Ltd
Gan & Lee Pharmaceuticals Co Ltd
Genexine Inc
Graduate School of Cancer Science and Policy
GSK plc
Guangdong 999 Brain Hospital
Henry Ford Health System
Huashan Hospital
ImmunityBio Inc
Immunomet Therapeutics Inc
Immvira Co Ltd
IN8bio Inc
Incyte Corp
Istari Oncology Inc
iXgene Inc
Jecho Biopharmaceuticals Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Kadmon Holdings Inc
Kairos Pharma Ltd
Karyopharm Therapeutics Inc
Kazia Therapeutics Ltd
Kite Pharma Inc
Komipharm International Co Ltd
Lixte Biotechnology Holdings Inc
Lumos Pharma Inc
Marino Biotechnology Co Ltd
Massachusetts General Hospital
Matrix Biomed Inc
Mayo Clinic
Medicenna Therapeutics Corp
MediciNova Inc
Merck & Co Inc
Merck KGaA
MimiVax LLC
Molecular Templates Inc
Mustang Bio Inc
NanoPharmaceuticals LLC
Neonc Technologies Inc
Nerviano Medical Sciences SRL
Neurosurgical Research Foundation
New York University
Northwestern University
Novartis AG
Oblato Inc
OncoTherapy Science Inc
Oryx GmbH & Co KG
OX2 Therapeutics Inc
Pfizer Inc
Photolitec LLC
Plus Therapeutics Inc
Polaris Pharmaceuticals Inc
Potenza Therapeutics Inc
Prelude Therapeutics Inc
Prestige BioPharma Ltd
Regeneron Pharmaceuticals Inc
Revolution Medicines Inc
Royan Institute
Shanghai Simnova Biotechnology Co Ltd
Shanghai Yuansong Biotechnology Co Ltd
Shenzhen Geno-Immune Medical Institute
Sichuan J.Z. Bio-chemical Science and Technology Development Co Ltd
Simcere Pharmaceutical Group Ltd
SonALASense Inc
Stanford University
Starlight Therapeutics Inc
Stemline Therapeutics Inc
Sumitomo Pharma Co Ltd
Suzhou Neupharma Co Ltd
Synermore Biologics Co Ltd
Taiho Oncology Inc
TargTex SA
Tasly Pharmaceutical Group Co Ltd
TheraBiologics Inc
Therapeia GmbH & Co KG
TRACON Pharmaceuticals Inc
Transgene SA
TVAX Biomedical Inc
UAB Minority Health and Health Equity Research Center
UCLAs Jonsson Comprehensive Cancer Center
University of North Carolina at Chapel Hill
University of Texas MD Anderson Cancer Center
Vaximm AG
VBI Vaccines Inc
Verastem Inc
Vigeo Therapeutics Inc
WPD Pharmaceuticals Inc
Xi'An Yufan Biotechnology Co Ltd
Xijing Hospital
Zai Lab Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Recurrent Glioblastoma Multiforme (GBM) reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Pharmaceuticals
New
Overweight and Obesity: Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024 in real time.

  • Access a live Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more